HighTide Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	56.8	81.23	136.67	43.43	48.06
Research & Development	267.97	363.53	311.57	182.65	84.01
Operating Expenses	324.77	444.75	448.24	226.08	132.08
Operating Income	-324.77	-444.75	-448.24	-226.08	-132.08
Interest Expense	-2.63	-1.53	-0.4	-0.43	-4.53
Interest & Investment Income	23.9	29.18	24.28	12.38	3.33
Currency Exchange Gain (Loss)	-0.49	3.12	-0.89	-7.52	0.6
Other Non Operating Income (Expenses)	19.66	38.79	8.17	8.2	5.28
EBT Excluding Unusual Items	-284.32	-375.2	-417.07	-213.45	-127.39
Gain (Loss) on Sale of Investments	-0.43	-6.11	-	-	-
Gain (Loss) on Sale of Assets	-0.21	-0.21	-	-	-0
Other Unusual Items	-	-	-522.16	23.24	-93.66
Pretax Income	-284.96	-381.52	-939.23	-190.21	-221.05
Income Tax Expense	-0.26	0.27	0.08	0.03	0.1
Net Income	-291.16	-381.79	-939.31	-190.24	-221.15
Net Income to Common	-291.16	-381.79	-939.31	-190.24	-221.15
Shares Outstanding (Basic)	452	452	260	255	42
Shares Outstanding (Diluted)	452	452	260	255	42
Shares Change (YoY)	26.18%	74.08%	1.91%	506.17%	-
EPS (Basic)	-0.64	-0.84	-3.62	-0.75	-5.26
EPS (Diluted)	-0.64	-0.84	-3.62	-0.75	-5.26
Free Cash Flow	-239.03	-302.75	-357.42	-172.56	-92.29
Free Cash Flow Per Share	-0.53	-0.67	-1.38	-0.68	-2.19
EBITDA	-323.44	-443.75	-447.7	-225.68	-131.8
D&A For EBITDA	1.33	1.01	0.54	0.41	0.28
EBIT	-324.77	-444.75	-448.24	-226.08	-132.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.